CSIMarket
 


Heska Corporation  (HSKA)
Other Ticker:  
 

Heska's Leverage Ratio

HSKA's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 6.99%, Leverage Ratio fell to 0.42, below the Heska's average Leverage Ratio.

Within In Vitro & In Vivo Diagnostic Substances industry in the first quarter 2023, 28 other companies have achieved lower Leverage Ratio than Heska in the I Quarter 2023. While Leverage Ratio total ranking has improved so far in the first quarter 2023 to 243, from total ranking in the forth quarter 2022 at 947 .

Explain Leverage Ratio?
Who are HSKA Customers?
What are HSKA´s Total Liabilities?


HSKA Leverage Ratio (Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
Y / Y Equity Change -2.55 % -3.13 % -6.2 % -3.8 % 0.78 %
Y / Y Total Liabilities Change 1.14 % -2.74 % -0.11 % 16.42 % 19.94 %
Leverage Ratio MRQ 0.42 0.39 0.4 0.41 0.4
HSKA's Total Ranking # 243 # 947 # 0 # 0 # 943
Seq. Equity Change -1.07 % 3.51 % -2.25 % -2.64 % -1.67 %
Seq. Total Liabilities Change 6.99 % 0.89 % -4.33 % -2.06 % 2.89 %



Leverage Ratio first quarter 2023 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 29
Healthcare Sector # 100
Overall Market # 243


Leverage Ratio Statistics
High Average Low
0.99 0.49 0.26
(Sep 30 2013)   (Jun 30 2018)




Financial Statements
Heska's Equity $ 418 Millions Visit HSKA's Balance sheet
Heska's Total Liabilities $ 175 Millions Visit HSKA's Balance sheet
Source of HSKA's Sales Visit HSKA's Sales by Geography


Cumulative Heska's Leverage Ratio

HSKA's Leverage Ratio for the trailling 12 Months

HSKA Leverage Ratio

(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
Y / Y Equity TTM Growth -2.55 % -3.13 % -6.2 % -3.8 % 0.78 %
Y / Y Total Liabilities TTM Growth 1.14 % -2.74 % -0.11 % 16.42 % 19.94 %
Leverage Ratio TTM 0.4 0.4 0.4 0.39 0.37
Total Ranking TTM # 950 # 1081 # 1048 # 1063 # 1068
Seq. Equity TTM Growth -1.07 % 3.51 % -2.25 % -2.64 % -1.67 %
Seq. Total Liabilities TTM Growth 6.99 % 0.89 % -4.33 % -2.06 % 2.89 %


On the trailing twelve months basis Despite of the net new borrowings of 6.99% during the twelve months period ending in I Quarter 2023 Heska has managed to unchanged Leverage Ratio in the I Quarter 2023 to 0.4, below Heska's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the In Vitro & In Vivo Diagnostic Substances industry HSKA recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has improved so far to 960, from total ranking in previous 12 month period at 63.

Explain Leverage Ratio?
Who are HSKA Customers?
What are HSKA´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the In Vitro & In Vivo Diagnostic Substances Industry # 0
Healthcare Sector # 1
Within the Market # 243


trailing twelve months Leverage Ratio Statistics
High Average Low
0.96 0.51 0.28
(June 30. 2014)   (Dec 31 2018)




Companies with similar Leverage Ratio in the quarter ending Mar 31 2023, within In Vitro & In Vivo Diagnostic Substances Industry Leverage RatioMar 31 2023 MRQ Total LiabilitiesMar 31 2023 MRQ Equity
Oncocyte Corporation  1.12 $ 42.317  Millions$ 37.933  Millions
Quidelortho Corp  0.76 $ 3,790.600  Millions$ 4,996.500  Millions
Alpha Teknova Inc   0.53 $ 48.934  Millions$ 92.087  Millions
Immucell Corp  0.53 $ 14.962  Millions$ 28.161  Millions
Neogen Corporation  0.44 $ 1,383.209  Millions$ 3,125.555  Millions
Heska Corporation  0.42 $ 175.044  Millions$ 417.671  Millions
Myriad Genetics Inc   0.40 $ 334.100  Millions$ 835.200  Millions
Biomerica Inc   0.37 $ 2.224  Millions$ 5.986  Millions
Intellia Therapeutics Inc   0.09 $ 103.383  Millions$ 1,190.843  Millions

Date modified: 2023-05-06T20:55:06+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com